More than two dozen state attorneys general are urging federal authorities to fine several large drug makers for curtailing the discounts they offer through a federal program for safety-net hospitals.
The state officials are concerned about the viability of the 340B drug discount program, which requires drug makers to offer discounts estimated to be 25% to 50% — but which can be much higher — on all outpatient drugs to hospitals and clinics serving low-income populations. There are about 12,700 so-called covered entities, including hospitals, in the program.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
What is it?
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What’s included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
